Literature DB >> 21400546

NT-proBNP provides incremental prognostic information in cardiac outpatients with and without echocardiographic findings.

Stefan Toggweiler1, Oliver Borst, Frank Enseleit, Matthias Hermann, Frank Ruschitzka, Thomas F Lüscher, Georg Noll.   

Abstract

BACKGROUND: Outpatients frequently present with elevated natriuretic peptides in the absence of an obvious cardiac abnormality or with normal natriuretic peptides despite echocardiographic findings. HYPOTHESIS: We aimed to determine the prognostic value of N-terminal pro B-type natriuretic peptide (NTpBNP) in outpatients with normal and abnormal echocardiography.
METHODS: A total of 433 cardiovascular outpatients were included. The prognostic value of NTpBNP in patients with normal and abnormal echocardiography during a 2-year follow-up was evaluated.
RESULTS: Patients with abnormal echocardiography and elevated NTpBNP had a mortality rate of 8.7% and an overall event rate of 20.2% (composite end point of overall mortality, myocardial infarction, and hospitalization for heart failure), which was significantly higher than in patients with abnormal echocardiography and normal NTpBNP, in which no mortality (P=0.011) and no events were observed (P<0.001). In patients with a normal echocardiography, mortality was 1.5% and 1.8% for patients with normal and elevated NTpBNP, respectively (P=1.000). Composite event rate was 1.5% and 8.9% (P=0.093), respectively.
CONCLUSIONS: Patients with low NTpBNP have an excellent prognosis irrespective of echocardiographic findings. Therefore, determination of NTpBNP appears useful in assessing the clinical relevance of echocardiographic findings.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21400546      PMCID: PMC6652603          DOI: 10.1002/clc.20894

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  5 in total

1.  NT-proBNP is associated with mortality and adverse cardiac events in patients with atrial fibrillation presenting to the emergency department.

Authors:  Marijn J Holl; Ewout J van den Bos; Ron T van Domburg; Michael A Fouraux; Marcel J Kofflard
Journal:  Clin Cardiol       Date:  2018-02-26       Impact factor: 2.882

2.  Serial measurements of N-terminal pro-brain natriuretic peptide in patients with coronary heart disease.

Authors:  Dhayana Dallmeier; Michael J Pencina; Iris Rajman; Wolfgang Koenig; Dietrich Rothenbacher; Hermann Brenner
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

3.  Think-aloud study about the diagnosis of chronic heart failure in Belgian general practice.

Authors:  Miek Smeets; Pieter De Witte; Sanne Peters; Bert Aertgeerts; Stefan Janssens; Bert Vaes
Journal:  BMJ Open       Date:  2019-03-20       Impact factor: 2.692

4.  The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study.

Authors:  Wen-Fei He; Lei Jiang; Yi-Yue Chen; Yuan-Hui Liu; Peng-Yuan Chen; Chong-Yang Duan; Li-Huan Zeng; Hua-Lin Fan; Xue-Biao Wei; Wei Guo; Wei Chen; Jun Li; Wen-Sheng Li; Zhi-Qiang Guo; Zhi-Kai Liu; Ning Tan; Ji-Yan Chen; Peng-Cheng He
Journal:  BMC Cardiovasc Disord       Date:  2021-04-21       Impact factor: 2.298

5.  Impact of an extended audit on identifying heart failure patients in general practice: baseline results of the OSCAR-HF pilot study.

Authors:  Miek Smeets; Bert Vaes; Bert Aertgeerts; Willem Raat; Joris Penders; Jan Vercammen; Walter Droogne; Wilfried Mullens; Stefan Janssens
Journal:  ESC Heart Fail       Date:  2020-09-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.